Federal Register Notice: FDA has determined the regulatory review period for Kissei Pharmaceutical’s Rapaflo is 3,681 days for extending a patent which claims the human drug product. Rapaflo (silodosin) is indicated for treating the signs and symptoms of benign prostatic hyperplasia. To view this notice, click here.
